Tourmaline Bio is focused on developing innovative therapies aimed at significantly improving the lives of patients suffering from immune and inflammatory diseases. Their lead product candidate, pacibekitug (also known as TOUR006), is a long-acting anti-IL-6 antibody designed to inhibit the IL-6 signaling pathway, which plays a crucial role in various autoimmune conditions. The company is advancing pacibekitug through multiple clinical phases, with key milestones expected in the near future, including Phase 2b topline data for Thyroid Eye Disease anticipated in the second half of 2025 and the initiation of Phase 3 trials for the same indication expected to begin in H2 2024.

The therapeutic strategy of Tourmaline Bio leverages the extensive clinical experience with IL-6 inhibitors, which have been successfully used in treating a range of autoimmune diseases for over two decades. By focusing on indications where IL-6 inhibition has shown potential but lacks formal development programs, Tourmaline aims to capitalize on emerging insights and data that support the efficacy of pacibekitug. The company’s approach is to validate the therapeutic potential of IL-6 inhibition further, utilizing a high binding affinity and long half-life of pacibekitug to provide effective treatment with minimal drug exposure and infrequent administration.

United States

Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Cardiovascular Diseases

Eye Diseases

Immune System Diseases

Inflammatory disorders

Tourmaline Bio

Atherosclerotic cardiovascular disease

Chronic kidney disease

Kidney disease

<p class="font_8">TOUR006 is a long-acting, fully human, anti-IL-6 monoclonal antibody with differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. TOUR006 has been previously studied in 448 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing TOUR006 in thyroid eye disease and atherosclerotic cardiovascular disease as its first two indications, with additional diseases under consideration.</p>

Pacibekitug (TOUR006)

Thyroid Eye Disease

Scleroderma

<p class="font_8">FCR001 is a cryopreserved &nbsp;allogeneic stem cell therapy derived from mobilized peripheral blood of &nbsp;the kidney donor that is delivered as a single dose in kidney transplant &nbsp;recipients who received a non-myeloablative conditioning regimen. &nbsp;FCR001 contains the donor's CD34+ cells, facilitating cells, and αβ T &nbsp;cells. This therapy induces or restores patients' immune tolerance by &nbsp;establishing stable donor chimerism in the transplant recipient without &nbsp;the need for life-long immunosuppression.</p>

Tourmaline Bio

Company Details